MarketWatch12hAutomated tone · bullish
Big pharma stocks close near all-time highs as tech selloff pushes investors toward safer betsShares of AbbVie, Eli Lilly and Gilead Sciences closed near record highs
Seeking Alpha2dAutomated tone · neutral
AbbVie releases phase 3 induction therapy data on injectable Skyrizi for Crohn'sInvesting.com2dAutomated tone · neutral
AbbVie reports positive Crohn’s disease trial results for SkyriziSeeking Alpha10dAutomated tone · neutral
AbbVie flags $216M IPR&D and milestones expense for Q3Seeking Alpha10dAutomated tone · bullish
Genmab, AbbVie data boosts Epkinly as first-line B-cell lymphoma treatmentSeeking Alpha12dAutomated tone · neutral
AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilotSeeking Alpha14dAutomated tone · neutral
AbbVie long-term data buoys Rinvoq for vitiligoSeeking Alpha15dAutomated tone · bearish
AbbVie's ABBV-295 delivers up to 9.8% weight loss in Phase 1Seeking Alpha16dAutomated tone · neutral
AbbVie reports positive phase 2 data for Zumilokibart in atopic dermatitisSeeking Alpha17dAutomated tone · bullish
AbbVie’s Juvmo wins FDA approval for Parkinson’s diseaseSeeking Alpha24dAutomated tone · bullish
AbbVie gains EU approval for Rinvoq to treat pediatric arthritisSeeking Alpha24dAutomated tone · neutral
AbbVie inks multi-year AI drug discovery deal with Iambic TherapeuticsInvesting.com29dAutomated tone · neutral
Cantor Fitzgerald reiterates Abbvie stock rating on drug dataSeeking Alpha40dAutomated tone · neutral
Key deals this week: Flex, Nvidia, AbbVie and moreSeeking Alpha42dAutomated tone · neutral
AbbVie seals $11B acquisition of Apogee TherapeuticsYahoo Finance46dAutomated tone · neutral
How Is AbbVie’s Stock Performance Compared to Other Healthcare StocksSeeking Alpha50dAutomated tone · bullish
AbbVie files for EMA approval of Skyrizi for Crohn’s disease treatmentInvesting.com55dAutomated tone · neutral
AbbVie presents lung cancer data at WCLC 2026 conferenceYahoo Finance56dAutomated tone · neutral
Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets AheadSeeking Alpha62dAutomated tone · neutral
Glenview adds Eli Lilly, AbbVie, trims CVS, AMAT, among top Q2 tradesYahoo Finance65dAutomated tone · neutral
AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?Yahoo Finance66dAutomated tone · neutral
AbbVie’s (ABBV) Botox Just Got A Step Closer To A Fifth UseYahoo Finance71dAutomated tone · neutral
Analyst Report: AbbVie IncYahoo Finance71dAutomated tone · bullish
Baron Capital Exits Apogee Therapeutics (APGE) Following AbbVie BuyoutSeeking Alpha76dAutomated tone · bullish
AbbVie forecasts 2026 adjusted EPS of $13.87-$14.07 as it expects ~$67.6B revenue and Q3 EPS of $3.84-$3.88Yahoo Finance76dAutomated tone · neutral
AbbVie Inc. Q2 2026 Earnings Call SummarySeeking Alpha76dAutomated tone · neutral
Earnings Snapshot: AbbVie tops Q2 expectations; lowers FY EPS guidance for M&A impactSeeking Alpha76dAutomated tone · neutral
AbbVie in Charts: Skyrizi and Rinvoq fuel growth as Humira decline continuesInvesting.com76dAutomated tone · neutral
Why is AbbVie stock sliding today?Investing.com76dAutomated tone · bullish
AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimatesSeeking Alpha76dAutomated tone · bullish
AbbVie Non-GAAP EPS of $3.65 beats by $0.04, revenue of $16.99B beats by $230MSeeking Alpha78dAutomated tone · neutral
AbbVie wins EU clearance for Rinvoq as first systemic treatment for non-segmental vitiligo